BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29950117)

  • 1. Emerging patents in the therapeutic areas of glioma and glioblastoma.
    Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
    Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel chemotherapeutics and other therapies for treating high-grade glioma.
    Kang JH; Adamson C
    Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of microRNA based diagnostics and therapeutics in glioma: a patent review.
    Mondal I; Kulshreshtha R
    Expert Opin Ther Pat; 2021 Jan; 31(1):91-106. PubMed ID: 33054467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging targeted therapies for glioma.
    Miller JJ; Wen PY
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
    Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
    Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current State of Immunotherapy for Treatment of Glioblastoma.
    McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
    Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
    Batich KA; Sampson JH
    Expert Opin Pharmacother; 2014 Oct; 15(14):2047-61. PubMed ID: 25139628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for malignant glioma.
    Mason WP
    Expert Opin Emerg Drugs; 2008 Mar; 13(1):81-94. PubMed ID: 18321150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
    Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
    Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
    Zhang X; Ding K; Wang J; Li X; Zhao P
    Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.
    Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS
    Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG-3 antagonists by cancer treatment: a patent review.
    Perez-Santos M; Anaya-Ruiz M; Cebada J; Bandala C; Landeta G; Martínez-Morales P; Villa-Ruano N
    Expert Opin Ther Pat; 2019 Aug; 29(8):643-651. PubMed ID: 31291131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.